$ATXS
Astria Therapeutics, Inc. Stock $atxs

$atxs Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000127 Filed on March 04, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.424M	$7.333M	$25.70M
YoY Change	54.29%	56.05%	33.6%
% of Gross Profit
Research & Development	$15.73M	$26.87M	$42.13M
YoY Change	95.77%	180.12%	22.95%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$24.15M	$34.20M	$83.03M
YoY Change	78.98%	139.32%	55.19%
Operating Profit	-$24.15M		-$83.03M
YoY Change	78.98%		55.19%
Interest Expense	$4.241M	$2.797M	$10.20M
YoY Change	82.72%	174.75%	491.71%
% of Operating Profit
Other Income/Expense, Net	$4.222M	-$8.000K	$10.14M
YoY Change	83.17%	-188.89%	507.49%
Pretax Income	-$19.93M	-$31.41M	-$72.89M
YoY Change	78.12%	136.82%	40.62%
Income Tax
% Of Pretax Income
Net Earnings	-$19.93M	-$31.41M	-$72.89M
YoY Change	78.12%	136.82%	40.62%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.38		-$2.42
Diluted Earnings Per Share	-$0.38	-$0.86	-$2.42
COMMON SHARES
Basic Shares Outstanding	54.90M	36.30M	30.12M
Diluted Shares Outstanding	52.29M		30.12M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$246.5M	$246.5M
YoY Change		8.87%	8.87%
Cash & Equivalents	$172.0M	$175.5M	$7.709M
Short-Term Investments		$71.00M	$71.00M
Other Short-Term Assets		$4.412M	$4.412M
YoY Change		252.11%	252.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$374.5M	$250.9M	$250.9M
YoY Change	73.84%	10.21%	10.21%
LONG-TERM ASSETS
Property, Plant & Equipment		$363.0K	$363.0K
YoY Change		-61.71%	-61.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.076M	$3.361M	$3.361M
YoY Change	104.93%	68.47%	68.47%
Total Long-Term Assets	$4.286M	$3.724M	$3.724M
YoY Change	53.35%	26.54%	26.54%
TOTAL ASSETS
Total Short-Term Assets	$374.5M	$250.9M	$250.9M
Total Long-Term Assets	$4.286M	$3.724M	$3.724M
Total Assets	$378.8M	$254.7M	$254.7M
YoY Change	73.57%	10.42%	10.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$862.0K	$1.513M	$1.513M
YoY Change	-7.31%	92.01%	92.01%
Accrued Expenses	$10.04M	$9.708M	$10.04M
YoY Change	94.76%	26.24%	21.34%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.07M	$11.55M	$11.55M
YoY Change	65.92%	27.48%	27.48%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.07M	$11.55M	$11.55M
Total Long-Term Liabilities		$0.00	$0.00
Total Liabilities	$11.07M	$11.55M	$11.55M
YoY Change	60.93%	22.65%	22.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$600.5M	-$580.5M
YoY Change	15.75%	14.36%
Common Stock	$55.00K	$41.00K
YoY Change	96.43%	46.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$367.7M	$243.1M	$243.1M
YoY Change
Total Liabilities & Shareholders Equity	$378.8M	$254.7M	$254.7M
YoY Change	73.57%	10.42%	10.42%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$19.93M	-$31.41M	-$72.89M
YoY Change	78.12%	136.82%	40.62%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$19.09M	-$30.24M	-$68.45M
YoY Change	44.07%	183.55%	57.23%
INVESTING ACTIVITIES
Capital Expenditures		$16.00K	$25.00K
YoY Change		-48.39%	-72.53%
Acquisitions
YoY Change
Other Investing Activities	-$126.2M	-$2.000M	$135.1M
YoY Change	-164.73%	-98.52%	-180.87%
Cash From Investing Activities	-$126.2M	-$2.016M	$135.1M
YoY Change	-164.74%	-98.51%	-180.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	141.8M	87.98M	88.40M
YoY Change	383162.16%	-26.93%	-38.92%
NET CHANGE
Cash From Operating Activities	-19.09M	-30.24M	-68.45M
Cash From Investing Activities	-126.2M	-2.016M	135.1M
Cash From Financing Activities	141.8M	87.98M	88.40M
Net Change In Cash	-3.518M	55.72M	155.0M
YoY Change	-101.94%	-318.98%	-335.07%
FREE CASH FLOW
Cash From Operating Activities	-$19.09M	-$30.24M	-$68.45M
Capital Expenditures		$16.00K	$25.00K
Free Cash Flow		-$30.25M	-$68.47M
YoY Change		182.88%	56.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001454789
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	atxs	Fair Value Liabilities Level1 To Level2 Transfers Amount1 FairValueLiabilitiesLevel1ToLevel2TransfersAmount1	0
CY2023Q4	atxs	Fair Value Liabilities Level1 To Level2 Transfers Amount1 FairValueLiabilitiesLevel1ToLevel2TransfersAmount1	0
CY2022Q4	atxs	Fair Value Liabilities Level2 To Level1 Transfers Amount1 FairValueLiabilitiesLevel2ToLevel1TransfersAmount1	0
CY2023Q4	atxs	Fair Value Liabilities Level2 To Level1 Transfers Amount1 FairValueLiabilitiesLevel2ToLevel1TransfersAmount1	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27501340
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41034797
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	atxs	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41034797
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37467
CY2023	dei	Entity Registrant Name EntityRegistrantName	Astria Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3687168
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	75 State Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1400
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02109
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	349-1971
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ATXS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	279504972
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54903061
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175530000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20525000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	71000000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	205912000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4412000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1253000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	250942000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	227690000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	363000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	948000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3361000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1995000
CY2023Q4	us-gaap	Assets Assets	254666000
CY2022Q4	us-gaap	Assets Assets	230633000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1513000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	788000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9708000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7690000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	329000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	582000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11550000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9060000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	357000
CY2023Q4	us-gaap	Liabilities Liabilities	11550000
CY2022Q4	us-gaap	Liabilities Liabilities	9417000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41034797
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27501340
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	28000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	728285000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	632512000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-79000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-580534000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507643000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	243116000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	221216000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	254666000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230633000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	42127000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34264000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25704000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19239000
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	15199000
CY2023	us-gaap	Operating Expenses OperatingExpenses	83030000
CY2022	us-gaap	Operating Expenses OperatingExpenses	53503000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-83030000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-53503000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	10201000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1724000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-62000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-55000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10139000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1669000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-72891000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-51834000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.42
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.55
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30123316
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30123316
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14620618
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14620618
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-72891000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-51834000
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	79000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-79000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	79000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-79000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72812000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51913000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	122311000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1542000
CY2022	atxs	Stock Issued During Period Value Underwriting Agreement StockIssuedDuringPeriodValueUnderwritingAgreement	107646000
CY2022	atxs	Stock Issued During Period Value New Issues At Market Offerings StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings	36991000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	85000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4554000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-79000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-51834000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	221216000
CY2023	atxs	Stock Issued During Period Value Underwriting Agreement StockIssuedDuringPeriodValueUnderwritingAgreement	59480000
CY2023	atxs	Stock Issued During Period Value New Issues At Market Offerings StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings	28498000
CY2023	atxs	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	420000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6314000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	79000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-72891000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	243116000
CY2023	us-gaap	Profit Loss ProfitLoss	-72891000
CY2022	us-gaap	Profit Loss ProfitLoss	-51834000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6314000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4554000
CY2022	atxs	Gain Loss On Warrant Inherited GainLossOnWarrantInherited	-1542000
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-585000
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	554000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	40000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-112000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4546000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1568000
CY2023	atxs	Increase Decrease In Right Of Use Asset Operating IncreaseDecreaseInRightOfUseAssetOperating	-610000
CY2022	atxs	Increase Decrease In Right Of Use Asset Operating IncreaseDecreaseInRightOfUseAssetOperating	574000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	725000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-766000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2018000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4407000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68445000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43533000
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1924423000
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	396064000
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	2059500000
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	229026000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	91000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	135052000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-167129000
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	59480000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	107646000
CY2023	atxs	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	28498000
CY2022	atxs	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	36991000
CY2023	atxs	Proceeds From Exercise Of Stock Options And Warrant Financial Activities ProceedsFromExerciseOfStockOptionsAndWarrantFinancialActivities	420000
CY2022	atxs	Proceeds From Exercise Of Stock Options And Warrant Financial Activities ProceedsFromExerciseOfStockOptionsAndWarrantFinancialActivities	84000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88398000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	144721000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	155005000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-65941000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20688000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86629000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175693000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20688000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1268000
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1074000
CY2023	atxs	Purchases Of Property And Equipment In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruedLiabilities	17000
CY2023	atxs	Offeringcostsincludedinaccruedexpenses Offeringcostsincludedinaccruedexpenses	120000
CY2022	atxs	Offeringcostsincludedinaccruedexpenses Offeringcostsincludedinaccruedexpenses	100000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1.</b> <b style="font-weight:bold;">Organization and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Astria Therapeutics, Inc. (the “Company”), is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. The Company’s lead product candidate is STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (“HAE”), a rare, debilitating and potentially life-threatening disease. The Company’s second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis (“AD”), an immune disorder associated with loss of skin barrier function and itching. The Company was incorporated in the State of Delaware on June 26, 2008.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">December 2022 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On December 15, 2022, the Company entered into an underwriting agreement with Jefferies LLC and Evercore Group LLC, representatives of several underwriters, relating to an underwritten public offering (the “December 2022 Financing”) of 9,082,653 shares (the “Shares) of common stock at a public offering price of $11.01 per share. The underwriters were also granted a 30-day option to purchase up to an additional 1,362,397 shares of common stock (the “Additional Shares”) on the same terms and conditions as the Shares. The underwriters elected to purchase the full amount of the Additional Shares on December 19, 2022 for a total amount of shares issued of 10,445,050. This resulted in gross proceeds of $115.0 million, and net proceeds of $107.6 million. The December 2022 Financing included 2,270,663 shares issued to related parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 4, 2023, the Company entered into a license agreement (the “License Agreement”) with Ichnos Sciences SA and Ichnos Sciences Inc. (collectively, “Ichnos”) pursuant to which Ichnos granted to the Company an exclusive (even as to Ichnos and its affiliates), worldwide, and sublicensable right and license to certain patent rights and related know-how (collectively, the “Licensed Intellectual Property”), to develop, manufacture, and commercialize Ichnos’ proprietary OX40 portfolio. The OX40 portfolio includes Ichnos’ proprietary OX40 antagonist monoclonal antibody, with the generic name telazorlimab and also referred to by Ichnos as “ISB 830” as well as Ichnos’ proprietary affinity matured next generation OX40 antagonist monoclonal antibody referred to by Ichnos as “ISB 830-X8” and referred to by the Company as “STAR-0310 candidate” (collectively, the “Licensed Compounds”). The Company agreed to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one product that contains or comprises a Licensed Compound (a “Licensed Product”) in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the License Agreement, the Company paid Ichnos a one-time upfront license fee of $15.0 million in October 2023. The Company is obligated to pay Ichnos up to $305.0 million in milestones, consisting of up to $20.0 million upon the achievement of certain development milestones, up to $70.0 million upon the achievement of certain regulatory milestones and up to $215.0 million upon the achievement of certain commercial milestones, in each case in up to three indications with respect to the first applicable Licensed Product to achieve such milestone events. The Company is also obligated to pay Ichnos tiered royalties ranging from a mid-single-digit percentage to a low-double-digit percentage on aggregate annual net sales of all Licensed Products. The Company is obligated to pay royalties on a Licensed Product-by-Licensed Product and country-by-country basis until the latest of: (i) the expiration of the last valid claim covering the composition of matter of such Licensed Product in such country; (ii) the expiration of the last regulatory exclusivity with respect to such Licensed Product in such country; and (iii) twelve years following the first commercial sale of such Licensed Product in such country. The royalty rate is subject to reduction on a Licensed Product-by-Licensed Product and country-by-country basis under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">October 2023 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On October 16, 2023, the Company entered into an underwriting agreement with Jefferies LLC and Evercore Group LLC, representatives of several underwriters, relating to an underwritten offering (the “October 2023 Financing”) of (i) 8,253,895 shares of common stock and accompanying common stock warrants to purchase an aggregate of 6,190,418 shares of common stock and (ii), in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 1,178,320 shares of common stock for aggregate gross proceeds of approximately $64.0 million, and net proceeds of $59.5 million. The October 2023 Financing included 2,727,340 shares of common stock, 3,223,824 common stock warrants, and 1,571,093 pre-funded warrants issued to related parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On June 30, 2021, the Company entered into an Open Market Sale AgreementSM with Jefferies LLC, or Jefferies, pursuant to which the Company was able to issue and sell shares of common stock of up to $25.0 million under an at-the-market offering program, or the Jefferies ATM Program. The Company was obligated to pay the sales agent commissions of 3% of the gross proceeds from any common stock sold through the Jefferies ATM Program. In September 2022, the Jefferies ATM Program was modified to increase the amount of the Company’s common stock that was able to be offered thereunder to an aggregate offering price of up to $50.0 million, with $30.5 million of such amount then being available for future issuance. In November 2022, the Jefferies ATM Program was once again modified to increase the amount of the Company’s common stock that was able to be offered thereunder to an aggregate offering price of up to $88.1 million, with $50.0 million of such amount then being available for future issuance. In the year ended December 31, 2022, the Company sold an aggregate of 4,012,003 shares of common stock under the Jefferies ATM Program for gross proceeds of $38.2 million and net proceeds of $37.0 million. In the year ended December 31, 2023, the Company sold an aggregate of 4,738,606 shares of common stock under the Jefferies ATM Program for gross proceeds of $29.4 million and net proceeds of $28.5 million. As of December 31, 2023, $20.6 million of common stock remained available for sale under the Jefferies ATM Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2023, the Company had an accumulated deficit of $580.5 million and had available cash, cash equivalents and short-term investments $246.5 million. The Company estimates its existing cash, cash equivalents, and short-term investments are sufficient to sustain operations for at least twelve months from the issuance of these consolidated financial statements. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional debt, equity or other financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company’s products. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.</p>
CY2021Q2	atxs	Percentage Of Commission Paid To Underwriter Based On Proceeds From Offering PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering	0.03
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-580500000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	246500000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Significant Suppliers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to credit risk primarily consist of cash, cash equivalents, short-term investments and restricted cash. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company's investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients, other raw materials and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients, other raw materials and formulated drugs.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175530000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20525000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	163000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	163000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175693000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20688000
CY2023Q4	atxs	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6314000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4554000
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16439156
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9026108
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2023Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15200000
CY2023Q4	us-gaap	Legal Fees LegalFees	200000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2023Q4	atxs	Accrued Contracted Research Costs Current AccruedContractedResearchCostsCurrent	3861000
CY2022Q4	atxs	Accrued Contracted Research Costs Current AccruedContractedResearchCostsCurrent	2822000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4047000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3373000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1485000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	588000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	315000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	407000
CY2022Q4	atxs	Accrued Milestone Costs Current AccruedMilestoneCostsCurrent	500000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9708000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7690000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	338000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	338000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	329000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	700000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	800000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	atxs	Number Of Preferred Stock Series NumberOfPreferredStockSeries	1
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7700596
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.30
CY2023	atxs	Warrants And Rights Outstanding Weighted Average Remaining Contractual Term WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm	P4Y7M6D
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41034797
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	23387610
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10076610
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.0012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.0066
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0344
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0388
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0625
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0567
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0161
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0125
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0058
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2901
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2811
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	85734000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	80136000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	14576000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	12073000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16927000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8094000
CY2023Q4	atxs	Deferred Tax Assets Capitalized Licenses DeferredTaxAssetsCapitalizedLicenses	4041000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	918000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	964000
CY2023Q4	atxs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	90000
CY2022Q4	atxs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	257000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2587000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2365000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	124873000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	103889000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	124774000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	103630000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	99000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	259000
CY2023Q4	atxs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	99000
CY2022Q4	atxs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	259000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16900000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	8100000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21100000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14600000

Files In Submission

Name	View Source	Status
0001410578-24-000127-index-headers.html	Edgar Link	pending
0001410578-24-000127-index.html	Edgar Link	pending
0001410578-24-000127.txt	Edgar Link	pending
0001410578-24-000127-xbrl.zip	Edgar Link	pending
atxs-20231231.xsd	Edgar Link	pending
atxs-20231231x10k.htm	Edgar Link	pending
atxs-20231231xex10d18.htm	Edgar Link	pending
atxs-20231231xex10d19.htm	Edgar Link	pending
atxs-20231231xex10d19001.jpg	Edgar Link	pending
atxs-20231231xex10d19002.jpg	Edgar Link	pending
atxs-20231231xex10d19003.jpg	Edgar Link	pending
atxs-20231231xex10d19004.jpg	Edgar Link	pending
atxs-20231231xex10d19005.jpg	Edgar Link	pending
atxs-20231231xex10d19006.jpg	Edgar Link	pending
atxs-20231231xex21d1.htm	Edgar Link	pending
atxs-20231231x10k_htm.xml	Edgar Link	completed
atxs-20231231xex23d1.htm	Edgar Link	pending
atxs-20231231xex31d1.htm	Edgar Link	pending
atxs-20231231xex31d2.htm	Edgar Link	pending
atxs-20231231xex32d1.htm	Edgar Link	pending
atxs-20231231xex32d2.htm	Edgar Link	pending
atxs-20231231xex97d1.htm	Edgar Link	pending
atxs-20231231xex97d1001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
atxs-20231231_def.xml	Edgar Link	unprocessable
atxs-20231231_lab.xml	Edgar Link	unprocessable
atxs-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
atxs-20231231_cal.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATXS
Astria Therapeutics, Inc. Stock $atxs

2024 Q1 Form 10-K Financial Statement

#000141057824000127 Filed on March 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXS Astria Therapeutics, Inc. Stock $atxs

2024 Q1 Form 10-K Financial Statement

#000141057824000127 Filed on March 04, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXS
Astria Therapeutics, Inc. Stock $atxs